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It has recently been shown that a T cellereplete allogeneic (allo) hematopoietic stem cell transplantation
(HSCT) from a haploidentical donor (haplo-ID) could be a valid treatment for hematological malignancies.
However, little data exist concerning older populations. We provided transplantation to 31 patients over the
age of 55 years from a haplo-ID and compared their outcomes with patients of the same ages who underwent
transplantation from a matched related (MRD) or an unrelated donor (UD). All 3 groups were comparable,
except for their conditioning. Patients in haplo-ID group received 2 days of post-transplantation high-dose
cyclophosphamide followed by cyclosporine A and mycophenolate mofetil, whereas patients in other groups
received pretransplantation antithymocyte globulin, cyclosporine A, and additional mycophenolate mofetil in
case of 1-antigen mismatch. All patients but 1 in the haplo-ID group engrafted. The incidence of grades 2 to 4
acute graft-versus-host disease (GVHD) was not statistically different between recipients from haplo-ID
(cumulative incidence, 23%) and MRD (cumulative incidence, 21%) transplantations but it was lower than
after UD HSCT (cumulative incidence, 44%). No patient in the haplo-ID group developed severe chronic GVHD,
compared with cumulative incidences of 16% and 14% after MRD (P ¼ .02) and UD (P ¼ .03) grafts, respectively.
The cumulative incidences of relapse were similar in the 3 groups, whereas nonrelapse mortality after UD
HSCT was 3-fold higher than after haplo-ID or MRD HSCT. Overall, 2-year overall survival (70%), progression-
free survival (67%), and progression and severe chronic GVHDefree survival (67%) probabilities after haplo-ID
did not statistically differ from MRD transplantation (78%, 64%, and 51%, respectively), although they
were higher than after UD transplantation (51% [P ¼ .08], 38% [P ¼ .02], and 31% [P ¼ .007]). We conclude that
T cellereplete haplo-ID HSCT followed by post-transplantation high-dose- cyclophosphamide in patients over
55 years is associated with promising results, similar to MRD HSCT, and is deserving prospective evaluation.
 2016 American Society for Blood and Marrow Transplantation.dgments on page 123.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Patients presenting with hematological malignancies
have a median age of 66 years [1]. Over the last decade,
reduced-intensity (RIC) or low-toxicity conditionings have
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allowing for HLA identical allogeneic (allo) hematopoietic
stem cell transplantation (HSCT) [2] in unﬁt or older patients
who were previously not considered for allo-HSCT [3].
However, most transplantation-eligible patients lack a suit-
able matched related (MRD) donor [4]. In addition, MRD to
elderly patients are elderly themselves, with frequent
conditions contraindicating donation. Matched (MUD) or
1-antigen mismatched (MMUD) unrelated donors are
frequently used when a suitable MRD is lacking, with pub-
lications reporting similar results. However, these publica-
tions have mainly described younger patients receiving
myeloablative conditioning and lack data from older pop-
ulations [5,6]. In addition, MMUD is not always found [4].
Presently, other alternative graft sources, such as unrelated
cord blood or 1 haplotypeematched related donor (haplo-
ID) are seldom used in older patients because these are
perceived as too toxic. Overall, this translates to a low rate of
allo-HSCT performed in a population with the highest inci-
dence of hematologic malignancies, who usually present
with the poorest prognosis unless allo-HSCT can be per-
formed. Thus, to meet this unmet medical need, it is critical
to develop innovative efﬁcient therapeutic strategies.
Recently, several teams successfully introduced T
cellereplete haplo-ID transplantation combining RIC or abla-
tive conditioning and new schemes for graft-versus-host
disease (GVHD) prophylaxis, reducing transplantation toxic-
ities and, in turn, increasing the number of patients who can
beneﬁt from an allo-HSCT. Because of decreased toxicity
documented with this transplantation technology when
compared with previous haplo-ID transplantation attempts,
this possibility may represent a real breakthrough in allowing
for an expanded number of patients needing an allo-HSCT
who can be offered an allo-HSCT. However, the suitability of
haplo-ID HSCT in the patients over age of 55 and who usually
present with more comorbidities remains unknown.
In this perspective, we report here a series of 31 patients
ages of 55 years or beyond with high-risk hematological
malignancies treatedwith an allo-HSCT from a related haplo-
ID using high-dose post-transplantation cyclophosphamide,
as previously described by the Johns Hopkins group [7]. This
cohort is compared to 2 series of patients with the same
characteristics who underwent transplantation from anMRD
or an unrelated donor (UD).
PATIENTS AND METHODS
From January 2011 until November 2013, 31 consecutive patients older
than 55 years underwent T-cell replete haplo-ID allo-HSCT for a hemato-
logical malignancy in institut Paoli Calmettes, Marseille and were included
in this analysis.
During the same period and in the same institution, 110 patients older
than 55 years received allo-HSCT from an MRD (n ¼ 47) or UD (n ¼ 63 of
whom 13 presented with 1-antigen mismatch) with all patients receiving a
similar RIC regimen [3,8]. Informed consent was obtained from all patients
included in this study approved by our institutional review board.
Inclusion Criteria
For patients with an allo-HSCT indication, our strategy according to
French standards was to ﬁrst try to identify an HLA identical or 1 anti-
genemismatched related or UD. In case such a donor was not identiﬁed,
patients were eligible for a haplo-ID allo-HSCT. Previous autologous and allo
HSCT were not considered contraindications. In case of previous allo-HSCT,
the initial donor was considered as ineligible for a second donation.
Overall patients were ineligible for allo-HSCT if they had uncontrolled
infections, active central nervous system disease, a Karnofsky performance
status <60%, or severe organ dysfunction, as previously reported [3,9].
The comorbidity index of each patient was calculated using the he-
matopoietic cell transplantationespeciﬁc comorbidity index [10]. Disease
risk index was retrospectively assessed, according to Armand et al. [11].Conditioning Regimen and GVHD Prophylaxis
For haplo-ID HSCT, the intensity of the conditioning regimen was pro-
gressively increased over timewhen experiencewith haplo-HSCTassociated
with the original nonmyeloablative conditioning (NMAC) regimen was felt
to be insufﬁcient for tumor control in high-risk patients, notably for patients
with myeloid malignancies. Thus, the initial NMAC consisted of cyclophos-
phamide (Cy) (14.5 mg/kg/day on days 6 and 5), ﬂudarabine (30 mg/m2/
day from days6 to2), and 2 Gy total body irradiation (day1) [12]. After
this, RIC included Cy (14.5 mg/kg/day on days 7 and 6), ﬂudarabine (30
mg/m2/day from days 6 to 2), and i.v. busulfan (130 mg/m2/day on
days 3 and 2). After this, thiothepa (5 mg/kg on day 6) was introduced
instead of pretransplantation Cy. In all cases, Cy (50 mg/kg/day) was
administered on days þ3 and þ4. Further GVHD prophylaxis consisted of
cyclosporine A and mycophenolate mofetil initiated on day þ5, as initially
reported [9,12].
RIC for MRD- or UD-based allo-HSCT was identical for all patients as
previously reported [3,8]. Fludarabine (30 mg/m2/day from day 6 to
day 2), i.v. busulfan (130 mg/m2/day on days 4 and 3), and antithy-
mocyte globulin (2.5 mg/kg on days 3 and 2) (Thymoglobulin; Genzyme,
St. Germain-en-Laye, France). GVHD prophylaxis consisted of cyclosporine A
starting on day 1, and mycophenolate mofetil was added in case of
1-antigenemismatched transplantation.Stem Cell Sources and Donors
For haplo-ID HSCT, potential family members were typed at the HLA-A,
HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci at a high-resolution level. All
the donor/recipient pairs exhibited a median of 4 mismatches (range, 2 to 5)
on the unshared haplotype. HLA antibody screening was performed in the
patient, as previously reported [9], to help determine donor choice. Zero to
1-antigenemismatched donors shared 6 or 5 of 6 antigens with the patient
(high-resolution molecular typing of HLA-A, -B, -DRB1) when related, or 10
or 9 of 10 antigens (high-resolution molecular typing of HLA-A, -B, -Cw,
-DRB1, and -DQ) when unrelated.
For the few donors who underwent bone marrow harvest under
general anesthesia, the target dose was 4  108 nuclear cells/kg of recip-
ient weight. Otherwise, most donors were mobilized with granulocyte
colonyestimulating factor (Granocyte; Chugai, France) with a CD34þ cells
target of 4  106/kg. Both harvest modalities have been previously
described [9]. Grafts were infused unmanipulated on day 0 except in case
of ABO incompatibility.
Supportive care has been previously reported [3,9].Engraftment and GVHD Evaluation
Neutrophil and platelet engraftment were deﬁned as previously re-
ported [9]. Acute and chronic GVHD (aGVHD and cGVHD, respectively) were
graded as previously reported [9], according to international criteria [13,14].Statistical Methods
We analyzed the cumulative incidences of aGVHD and cGVHD, non-
relapse mortality (NRM), and relapse or progression using competing risk
analysis and Gray test for comparison among groups [15]. Death without
evidence of relapsewas considered as a competing event for the incidence of
relapse. Similarly, the occurrence of relapse was considered as a competing
event for the incidence of NRM, whereas relapse, progression, and deaths
were treated as competing risks when analyzing the incidence of GVHD.
Progression-free survival (PFS) and overall survival (OS) were calculated
using the Kaplan-Meier method, and results were compared using the log-
rank test [16]. A P value < .05 was considered signiﬁcant. We also compared
the 3 groups using a composite endpoint integrating the probability of
survival without progression or development of extensive cGVHD, as pre-
viously described [17]. All survival analyses were computed on the R 3.1.0
statistical software (http://www.R-project.org). Data from haplo HSCTgroup
were compared with those from MRD and UD HSCT groups.RESULTS
Patient and transplantation characteristics are reported in
Table 1. UD were more often cytomegalovirus negative. Pe-
ripheral blood stem cells were more often collected from
MRD than from haplo-ID (P¼ .02) and NMACwas more often
used in haplo-ID HSCT recipients (P < .0001, see Table 1 for
further details).
All but 1 patient engrafted with a longer time to recon-
stitute platelets counts after haplo-ID HSCT (Table 2).
Table 1
Patient and Transplantation Characteristics
Characteristic Haplo
n ¼ 31
MRD
n ¼ 47
UD
n ¼ 63
Haplo versus
MRD
Haplo versus
UD
Year of transplantation, median (range) 2013 (2011-2013) 2012 (2011-2014) 2012 (2011-2013) NS NS
Age, median (range), yr 62 (56-73) 62 (55-71) 64 (57-71) NS NS
Gender NS NS
Male 17 (55%) 28 (61%) 30 (48%)
Female to male 19% 31% 13%
CMV NS .01
þ Donor/ recipient 15% 10% 48%
þ Donor/þ recipient 54% 64% 24%
 Donor/ recipient 24% 16% 24%
 Donor/þ recipient 7% 10% 4%
Diagnosis NS NS
AML 10 (32%) 14 (30%) 18 (29%)
ALL 1 (3%) 4 (8%) 5 (8%)
MDS 5 (16%) 5 (10%) 12 (19%)
MPD e 2 (4%) 2 (3%)
HL 2 (6%) e 1 (1%)
NHL 7 (22%) 10 (21%) 13 (21%)
CLL 3 (10%) 4 (8%) 3 (5%)
MM 3 (10%) 7 (32%) 7 (11%)
CML e 1 (2%) 2 (3%)
Time from diagnosis to HSCT, median (range), mo 14 (3-215) 8 (2-179) 23 (5-279) NS NS
Status at transplantation NS NS
CR 19 (61%) 28 (60%) 44 (70%)
Active disease 12 (39%) 19 (40%) 19 (30%)
Disease risk index NS NS
Low 3 (10%) 5 (11%) 6 (10%)
Intermediate 17 (55%) 30 (64%) 40 (63%)
High-very high 11 (35%) 12 (25%) 17 (27%)
Previous transplantation NS NS
Autologous 5 (16%) 11 (23%) 12 (19%)
Allogeneic 2 (6%) 0 0
Donor origin NA NA
Sibling 14 (45%) 47 (100%) e
Offspring 17 (55%) e e
Unrelated 63 (100%)
HCT-CI NS NS
0-1 9 (29%) 14 (31%)* 16 (28%)y
2 4 (13%) 9 (20%) 15 (26%)
3 18 (58%) 24 (55%) 26 (49%)
Stem cell source .02 NS
PBSC 27 (87%) 47 (100%) 60 (95%)
BM 4 (13%) 3 (5%)
Conditioning regimen <.0001 <.0001
NMAC 21 (68%) e e
RIC 10 (32%) 47 (100%) 63 (100%)
NS indicates not signiﬁcant; CMV, cytomegalovirus; ALL, acute lymphoid leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorders; HL,
Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; CML, chronic myeloid leukemia; CR, complete
remission; HCT-CI, hematopoietic cell transplantationespeciﬁc comorbidity index; NA, not appropriate; PBSC, peripheral blood stem cells; BM, bone marrow.
Data presented are n (%), unless otherwise indicated.
* HCT-CI was available for 44 patients.
y HCT-CI was available 58 patients.
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As reported inTable 2, the cumulative incidences of grades
2 to 4 or grades 3 and 4 aGVHDwere not statistically different
between the haplo-ID and MRD transplantations but there
was a trend for a lower incidence after haplo-ID than after any
UD HSCT. No haplo-ID patient developed severe cGVHD,
compared with a cumulative incidence of 16% and 14% after
MRD (P ¼ .02) and UD (P ¼ .03) grafts, respectively.
NRM, Relapse, and Survival
The median (range) follow-up of surviving patients was
23 (range, 6 to 43) months, with 22, 24, and 24months in the
Haplo, MRD, and UD groups, respectively. The cumulative
incidences of NRM were similar after haplo-ID and MRD
transplantations but was 3-fold higher after UD HSCT(Table 2). Of note, no patients died from GVHD after haplo-ID
HSCT, compared with 4 and 17 after MRD (P ¼ .09) and UD
(P ¼ .001), respectively. The cumulative incidences of relapse
were similar in the 3 groups occurring at a median of 7
months (range, 5 to 24) after HSCT. Overall, 17 patients died
from disease progression without any difference between
the 3 groups (19%, 11%, and 10% after haplo-ID, MRD, and UD
grafts, respectively). The 2-year OS and PFS probabilities
were not different between haplo-ID and MRD trans-
plantations but were higher in haplo-ID recipients compared
with those in the UD group (Table 2, Figure 1). Eventually,
patients in the haplo-ID group presented with 2-year cGVHD
PFS probability of 67% versus 51% and 31% in the MRD (P ¼
not signiﬁcant) and UD (P ¼ .007) groups, respectively
(Table 2, Figure 2).
Table 2
Clinical Results
Outcome Haplo
n ¼ 31
MRD
n ¼ 47
UD
n ¼ 63
Haplo versus
MRD
Haplo versus
UD
Engraftment, Days, median (range)
ANC > 500 20 (15-38) 18 (14-25) 17 (13-35) NS NS
PLT > 20000 29 (10-61) 11 (9-20) 11 (5-84) <.0001 <.0001
aGVHD
Grade 2-4 23% (8-38) 21% (9-33) 44% (32-57) NS .05
Grade 3-4 10% (0-20) 13% (3-22) 25% (15-36) NS .07
2 year cGVHD
Overall 13% (1-25) 35% (21-50) 24% (13-35) .03 .22
Severe 0% 16% (5-26) 14% (6-23) .02 .03
2 year NRM 10% (0-20) 11% (2-20) 34% (22-45) NS 0.01
2 year Relapse/progression 23% (8-39) 25% (11-40) 31% (18-43) NS NS
2 year OS 70% (54-86) 78% (66-90) 51% (38-64) NS .08
2 year PFS 67% (50-84) 64% (49-79) 38% (23-49) NS .02
2 year PFS without severe cGVHD 67% (50-84) 51% (35-67) 31% (16-40) NS .007
Causes of nondisease-related death
GVHD 4 (80%) 17 (68%)
Infection 1 (33%) 3 (12%)
Organ toxicity 1 (33%) 4 (16%)
Secondary cancer 1 (20%) 1 (4%)
Accident 1 (33%)
ANC indicates absolute neutrophil count; PLT, platelet.
Data presented are n (%), unless otherwise indicated.
D. Blaise et al. / Biol Blood Marrow Transplant 22 (2016) 119e124122DISCUSSION
Haplo HSCT using T cellereplete grafts is presently being
developed worldwide with increasing reports of alleviation
of the initial concerns about engraftment failures and GVHD.
Indeed, haplo HSCT has the potential advantage of permit-
ting a rapid donor identiﬁcation for virtually every single
patient: this allows for a timely transplantation limiting the
risk of relapse before transplantation in contrast to the time
needed to identify and qualify an UD. Additionally, this
avoids the costs associated with an UD search and graft
procurement. The use of a T cellereplete graft also has the
beneﬁt of avoiding sophisticated and expensive cell pro-
cessing, making this method affordable to most trans-
plantation centers. Although several other platforms using T
cellereplete grafts have been developed [18-21], the scheme
pioneered by the Johns Hopkins University group is charac-
terized by its relative simplicity, low incidences of cGVHD
and post-transplantation NRM, and an easy reproducibility
[12,22-24].
In this report, all patients were older than 55 years with a
median age of 62 years. The age of this cohort is deﬁnitively
higher than the median age in previous reports of haplo-ID0 12 24 36 48
0
50
100
Figure 1. Progression-free survival (Haplo versus MRD: P ¼ NS; Haplo versus
UD: P ¼ .02). Plain line: Haplo HSCT; dashed line: MRD HSCT; dotted line: UD
line. X axis: months after transplantation.HSCT that ranged from 25 to 48 years [12,18,20,21,25,26].
The Johns Hopkins group reported, at a conference in 2013,
the outcome of a large series of 273 patients with a median
age of 61 (range, 50 to 75) years with promising results [27].
The 31 haplo-ID recipients we reported here achieved a
2-year OS and PFS of 70% and 67%, respectively. When taking
into account that the median age was 62 years, that 58% of
the patients had a hematopoietic cell transplantation co-
morbidity index of 3 or more, and that 35% of the patients
had a high or very-high disease risk index, these results can
be, at the minimum, considered encouraging. Results are
similar to those achieved after HLA-identical sibling HSCT in
older patients, illustrating the real progress achieved in
allogeneic HSCT in this population, in major part because of
the introduction of NMAC and RIC. However, the lower
cGVHD occurrence and severity after haplo-ID HSCT set the
stage for a better quality of life, even though prospective
comparison remains to be performed. The 2-year PFS in the
haplo-ID cohort was 67% statistically higher than that
observed in the UD group (38%) (P ¼ .02). The outcomes we
report in our UD cohort are similar to those recently reported
in the literature for this range of age [28-30], although0 12 24 36 48
0
50
100
Figure 2. Severe cGVHD-free and progression-free survival (Haplo versus
MRD: P ¼ NS; Haplo versus UD: P ¼ .007). Plain line: Haplo HSCT; dashed line:
MRD HSCT; dotted line: UD line. X axis: months after transplantation.
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attributed to the use of an intermediate dose of antithymo-
cyte globulin. First, in a recent large analysis from the Center
for International Blood and Marrow Transplant Research
(CIBMTR) focusing on the use of RIC for AML patients,
McClune et al. reported a 2-year DFS of 31% and 34% for
patients ages 60 to 64 and 65, respectively, with one half of
the patients receiving HSCT fromMRD [28]. Our results from
UD HSCT are similar to reported younger populations in the
United States and Europe: Saber et al. reported for the
CIBMTR a 3-year OS and LFS of 37% and 34%, respectively,
after HSCT from 8/8 UD in 1193 patients with AML with a
median age of 51 years [29]. A recent Italian prospective
evaluation of MUD using RIC and ex vivo T cell depletion
reported 5-year OS and PFS of 39 and 29%, respectively, in a
population with a median age of 41 years [30]. Finally, the
role of alternative donors in older patients has been recently
evaluated by a retrospective study from CIBMTR [31], which
included 740 AML patients older than 50 years (median, 58
years). Results after MUD (8/8) HSCT were compared with
those achieved after HSCT from 7/8 UD or cord blood. As
mentioned by the authors, only 29 haplo-ID HSCT done for
AML in patients aged older than 55 years were reported to
CIBMTR in the same period, precluding any comparison.
Overall the 3-year PFS was not different between MUD (39%)
and MMUD (34%) HSCT but was higher than after cord blood
transplantation (29%). The similarity of results between
MMUD and MUD will need further conﬁrmation. Age was a
determining factor of outcomes, with a signiﬁcant excess of
death in the patients older than 60 years.
An interesting ﬁnding of the present study may be that
despite lower cGVHD in the haplo-ID cohort, disease control
is at least as effective as it is after MRD or UD transplantation.
Indeed, incidence of relapse or progression was 23% after
haplo HSCT versus 25% and 31% after MRD and UD, respec-
tively (P ¼ not signiﬁcant). This was even achieved when
patients receiving HSCT from haplo-ID grafts were prepared
with a lower intensity conditioning, which has been shown
to affect disease control in other studies [32]. This observa-
tion is important, as it suggests a good antitumor effect after
this procedure, which in other reports remains controversial.
To better appreciate the post-transplantation effect of
HSCT according to donor, we used a composite endpoint
combining death, disease progression, and severe cGVHD
incidence [17]. This composite endpoint represents an effort
to assess the quality of life (QOL) of patients surviving
without disease, taking severe cGVHD as a surrogate marker
of this QOL, as severe cGVHD remains the most important
event affecting QOL after transplantation [33]. This com-
posite endpoint was more often reached after haplo HSCT
than after transplantation from any other donor source.
This analysis is hampered by the usual limitations related
to its retrospective nature: possible patient selection biases,
not sufﬁcient control population, and heterogeneity in
diagnosis and conditioning regimens. However, this is an
analysis from a single institution reporting a relatively large
number of older patients treated over a short and recent
period of time, allowing for some homogeneity.
Altogether, these results invite investigation of the place
of haplo-ID, compared with the use of allo-HSCT from an UD,
for older patients with suitable a haplo-ID. For these reasons,
the French Institut National du Cancer has recently granted
funding for a prospective national study investigating the
relative role of haplo-ID versus UD HSCT when an MRD does
not exist for patients more than 55 years of age.ACKNOWLEDGMENTS
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